Aspire Biopharma Holdings, Inc.
ASBP
Get informed when a big investor buys or sells
+ FollowMarket Cap$71.75M
Close$
$-0.25
104.3% downside
Current Fair Value
104.3% downsideOvervalued by 104.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $71.75 Million |
|---|---|
| Enterprise Value | $66.39 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-16.38 |
| Beta | 0.21 |
| Outstanding Shares | 156,685 |
Return
| Return on Equity | -304.07% |
|---|---|
| Return on Assets | -165.27% |
| Return on Invested Capital | -154.39% |
Valuation & Multiples
| P/E Ratio | -0.07 |
|---|---|
| PEG | 0.09 |
| Price to Sales | - |
| Price to Book Ratio | 0.24 |
| Enterprise Value to Revenue | 1921.35 |
| Enterprise Value to EBIT | -10.85 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 15, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.70%▼ 1.93% |
|---|---|
| Total Invested | $8,453▼ 99.06% |
| Investors Holding | 2▼ 28.00% |
ESG Score
No data
About Aspire Biopharma Holdings, Inc.
2 employees
CEO: Mr. Kraig T. Higginson Aspire Biopharma Holdings, Inc. is a biotechnology company specializing in advanced diagnostic solutions and molecular testing. The company focuses on developing high-precision assays for disease detection, leveraging cutting-edge resear...